



**ONLY\* MAVENCLAD<sup>®</sup>**  
**CAN DELIVER 4 YEARS OF HIGH**  
**EFFICACY\*\* WITH A MAXIMUM OF**  
**20 DAYS OF ORAL DOSING<sup>†1-3</sup>**

**REFERENCES:** **1.** Giovannoni G et al. *Lancet Neurol* 2011; 10:329–337. **2.** Giovannoni G et al. *Mult Scler* 2018; 24:1594–1604. **3.** MAVENCLAD<sup>®</sup> SmPC, 2018. **4.** Merkel B et al. *Autoimmun Rev* 2017; 16:658–665. **5.** Coles A. *Ann Indian Acad Neurol* 2015; 18:S30–S34. **6.** Ziemssen T et al. *Mult Scler Relat Disord* 2015; 4:460–469. **7.** Schreiner TL, Miravalle A. *J Cent Nerv Syst Dis* 2012; 4:1–14.

\* There are currently no head-to-head trials. From publicly available information, accurate at date of creation – July 2019

\*\* vs. placebo. The term ‘high efficacy’ is generally accepted in MS literature<sup>4-7</sup>

<sup>†</sup> The recommended cumulative dose of MAVENCLAD<sup>®</sup> is 3.5 mg/kg body weight over 2 years, administered as 1 treatment course of 1.75 mg/kg per year. Each treatment course consists of 2 treatment weeks, one at the beginning of the first month and one at the beginning of the second month of the respective treatment year. Each treatment week consists of 4 or 5 days on which a patient receives 10mg or 20mg (1 or 2 tablets) as a single daily dose, depending on body weight<sup>3</sup>